UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Phase 0 Completed 8 enrolled Megan Daly, MD EMD Serono · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.

Timeline

Start: 2017-05-17
Primary completion: 2020-04-09
Completion: 2020-06-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	10 mg/kg	Intravenous

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Summary

Timeline

Drugs

Indications